News

Valneva and Pfizer today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new…

26 Feb'21

Pauline Jung and Lukas Leiendecker from the Obenauf Lab won the very first edition of the President’s Prize of the Austrian Society of Dermatology and…

25 Feb'21

Valneva reported today its full year unaudited consolidated financial results for the year ending December 31, 2020 and summarized its key…

22 Feb'21

Valneva announced that it has initiated the clinical lot-to-lot consistency Phase 3 study for its single-shot chikungunya vaccine candidate, VLA1553.

…

16 Feb'21

The Max Perutz Labs are rebuilding key parts of the institute. The opening of the new entrance, reception, and study space for students marks a first…

11 Feb'21

Researchers at IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – unveil functional and mechanistic details in small…

08 Feb'21

STED nanoscopy reveals substructures of the synaptonemal complex.

The protein kinase Ataxia-telangiectasia mutated (ATM) is at the heart of the cellular response to DNA double-strand breaks (DSBs). Using…

05 Feb'21

Joao Matos was born in Portugal, did his PhD at the Max Planck Institute of Molecular Cell Biology and Genetics (Germany), and carried out…

01 Feb'21

Valneva reported that the UK Government has exercised its option to order 40 million doses of its inactivated, adjuvanted COVID-19 vaccine candidate…

28 Jan'21

Valneva announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies,…

26 Jan'21

The Plant Sciences Facility at Vienna Biocenter was interviewed in the Austrian national daily newspaper Die Presse about its high-tech research into…

26 Jan'21

Check full video on YouTube: https://www.youtube.com/watch?v=csci5pl_8gY

We thank our customers and supporters by showcasing some highlights as well…

Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

IMP PhD students win the President’s Prize of the Austrian Society of Dermatology and Venereology

Valneva Reports FY 2020 Results and Major Corporate Achievements

Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate

Tearing down walls for a new beginning

Silencing by crosstalk

Shedding new light on an old problem

“Basic research and teaching should go hand-in-hand”

Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine

Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment

VBC Plant Sciences Facility interviewed in Die Presse

Biolution proudly presents its new demo reel